Mindray Acquires Controlling Stake in Shanghai Company

By LabMedica International staff writers
Posted on 11 Mar 2014
Mindray Shenzhen (China) has reached an equity transfer agreement with Long Island Biotec. Co., Ltd. (Long Island; Shanghai, China) through which Mindray will acquire a controlling stake in the company. Mindray will gain sales capabilities in thrombotic and hemostatic products and the deal will help the company meet market needs for surgery screening tests and detection of cardiovascular disease.

After the share transfer, Long Island will benefit from Mindray’s well-established R&D, engineering, production, sales, and marketing platforms, as well as its overall management. By combining Long Island’s strength in the field of thrombotic and hemostatic reagent products and Mindray’s advantages as a medical equipment maker, Long Island will raise the quality of both products and customer services. The combined company will broaden development opportunities for employees, and help Long Island establish a stronger position to compete in the marketplace.

Mindray develops, manufactures, and markets medical devices worldwide. The global headquarters are in China and the US headquarters are in Mahwah (NJ, USA). The company supplies a broad range of products across three primary business segments, patient monitoring and life support, in-vitro diagnostics, and medical imaging systems.

Related Links:

Mindray 
Long Island Biotec



Latest Industry News